

# Gastrointestinal (GI) Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



### NEOADJUVANT

**A022104/Janus Trial**  
(Triplet vs. double chemo)

Coord: A. Ballard  
PI: Dr. Zell  
Accrual: 6/15

**CCTG-CO32**  
(NEO-RT trial)  
**(opened 4/29/24)**

Coord: P. Yang  
PI: Dr. Zell  
Accrual: 2/5

**UCI 21-67**  
(Epacadostat + short course  
radiation + chemo)

PI: Dr. Valerin  
Pending activation

### ADJUVANT

**NRG-GI008/CIRCULATE**  
(ctDNA guided tx)

**(opened 9/14/22)**

Coord: A. Ballard  
PI: Dr. Zell  
Accrual: 2/5

### INTRA-OPERATIVE

**UCI 20-163**  
(SOC vs CG-100 Intraluminal)  
**(opened 10/11/24)**

Coord: M. Nguyen  
PI: Dr. Carmichael  
Accrual: 2/10  
Bypass Device

### MOLECULAR FAILURE

**UCI 20-43**  
(TAS102 + irinotecan)

Coord: K. Ghio  
PI: Dr. Dayyani  
Accrual: 5/11



### 1L METASTATIC

#### A022101

(at least 4 months of chemo once metastatic disease is confirmed)

(opened 12/13/23)

Coord: A. Ballard

PI: Dr. Eng  
Accrual: 0/2

### 2L METASTATIC

### 3L METASTATIC

#### UCI 21-39

(Pembro + TATE)

Coord: LM Aguilar

PI: Dr. Abi-Jaoudeh  
Accrual: 19/30



■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

Newly Diagnosed

Advanced/Metastatic

## Neoadjuvant

**UCI 21-191**  
(SOC therapy with ctDNA testing)

Coord: A. Ballard  
PI: Dr. Dayyani  
Pending activation

**UCI 23-184**  
Pafolacianine for Imaging of Peritoneal Carcinomatosis  
**(opened 11/13/24)**  
Coord: LM Aguilar  
PI: Dr. Senthil  
Accrual: 0/10

## ESCC

**UCI 24-77**  
(I-DXd)

Coord: TBD  
PI: Dr. Dayyani  
Pending activation

## Newly Diagnosed Metastatic

**UCI 20-87**  
(IV Paclitaxel + IV 5- FU + IV leucovorin + IP paclitaxel)

Coord: LM Aguilar  
PI: Dr. Senthil  
Accrual: 27/40

**A022102**  
(mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab)

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 7/14

**UCI 21-10**  
(FOLFOX + nivo + Bispecific antibody (anti-CLDN18.2 + anti-4-1BB))

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 14/17

**EA2183**  
(SOC + XRT)  
**(reopened 6/13/24)**

Coord: J. Koff  
PI: Dr. Hong  
Accrual: 0/7

## Recurrent

**UCI 23-78**  
(EGFR and MET-directed antibody)  
**(opened 3/1/24)**

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 0/3

**UCI 23-109**  
(Disitamab Vedotin + Tucatinib)  
**(opened 4/25/24)**

Coord: M. Nguyen  
PI: Dr. Dayyani  
Accrual: 2/10

**UCI 23-200**  
(AZD0901)  
**(opened 7/24/24)**

Coord: J. Koff  
PI: Dr. Dayyani  
Accrual: 3/10

**UCI 23-173**  
(ICI in ARID1a Mu)  
Coord: TBD  
PI: Dr. Dayyani  
Pending activation

**UCI 16-94**  
(Tirapazamine, Nivolumab)

Coord: LM Aguilar  
PI: Dr. Abi-Jaoudeh  
Accrual: 29/40

**UCI 22-51**  
(ASP2138)

Coord: N. Ferrand/  
P. Yang  
PI: Dr. Dayyani  
Accrual: 15/20

**UCI 24-49**  
**(opened 10/22/24)**  
(Beamion BCGC-1: Oral Zongertinib + Trastuzumab Deruxtecan or + Trastuzumab Emtansine)

Coord: M. Nguyen  
PI: Dr. Dayyani  
Accrual: 0/10

# Advanced Solid Tumors By Biomarker

## HER-2

ETCTN-10358/DASH  
(DS8201a + AZD6738)  
**(opened 5/5/23)**

Coord: M. Nguyen

PI: Dr. Dayyani  
Accrual: 2/3

UCI 20-67  
(Anti-PD-1 DF1001  
(monotherapy or  
combination therapy))

Coord: M. Nguyen

PI: Dr. Valerin  
Accrual: 18/29

UCI 24-49  
**(opened 10/22/24)**  
(Beamion BCGC-1:  
Oral Zongertinib +  
Trastuzumab Deruxtecan  
or + Trastuzumab  
Emtansine)

Coord: M. Nguyen  
PI: Dr. Dayyani  
Accrual: 0/10

## BRAF

## KRAS

UCI 24-65  
(FMC-376 in KRASG12C)  
**(opened 11/4/24)**

Coord: P. Yang

PI: Dr. Dayyani  
Accrual: 0/5

## EGFR

UCI 22-171  
(Anti-PD-1 +/- DF9001)  
**(opened 7/17/24)**

Coord: M. Nguyen  
PI: Dr. Valerin  
Accrual: 4/25

## CLDN18.2

UCI 22-51  
(ASP2138)

Coord: N. Ferrand/  
P. Yang  
PI: Dr. Dayyani

Accrual: 15/20

UCI 23-200  
(AZD0901)  
**(opened 7/24/24)**

Coord: J. Koff  
PI: Dr. Dayyani

Accrual: 3/10

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended



**UCI 23-85**  
(BA3182 + (EPCAM)/CD3  
Antibody)

**(opened 9/19/24)**

Coord: J. Balangué

PI: Dr. Valerin  
Accrual: 0/5

**UCI 22-26**  
(Androgen and  
glucocorticoid receptor  
antagonist)

Coord: K. Ghio

PI: Dr. Dayyani  
Accrual: 8/12

**ETCTN-10579**  
(ZEN003694 (ZEN-3694)  
+ capecitabine)

**(opened 10/27/23)**

Coord: P. Yang

PI: Dr. FC Lee  
Accrual: 2/4

**UCI 23-197**  
(DF6215)

**(opened 7/12/24)**

Coord: M. Nguyen

PI: Dr. Valerin  
Accrual: 1/5

**UCI 21-241**  
(ALK inhibitor NLV-655)

**(opened 7/12/24)**

Coord: A. Ballard

PI: Dr. Valerin  
Accrual: 17/25



**UCI 03-03**

(Immunologic response analysis)

Coord: B. Sanchez  
PI: Dr. Imagawa  
Accrual: 336/400

**UCI 23-29**

(Electroacupuncture in symptom management after CRS/HIPEC)

**(opened 8/8/24)**  
PI: Dr. Eng  
Accrual: 0/15

**UCI 20-04**  
**(Tissue Collection)**

Coord: B. Sanchez  
PI: Dr. Dayyani  
Accrual: 100/130

**UCI 22-55**

(ID GenomeSig for HomoRecomboDeficiency inPC & Mismatch RepairDeficiency in Microsatellite Instable CC)

PI: Dr. Pannunzio/Dr. Valerin  
Pending activation